Daily Banking News
$42.39
-0.38%
$164.24
-0.07%
$60.78
+0.07%
$32.38
+1.31%
$260.02
+0.21%
$372.02
+0.18%
$78.71
-0.06%
$103.99
-0.51%
$76.53
+1.19%
$2.81
-0.71%
$20.46
+0.34%
$72.10
+0.28%
$67.30
+0.42%

The Medical Cannabis and Wellness ETF PM says GW Pharma deal validates


The Medical Cannabis and Wellness UCITS ETF (LON:CBDP) Portfolio Manager Nawan Butt offers his thoughts on the recent $7.2B acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals, and how this deal will affect the medical cannabis sector.

GW Pharmaceuticals makes up 14% of the Medical Cannabis and Wellness UCITS ETF’s portfolio. The fund, that falls under the HANetf umbrella, recently celebrated its one year anniversary, has delivered a return of 39.47% over the past three months and 40.41% over the last 12 months.



Read More: The Medical Cannabis and Wellness ETF PM says GW Pharma deal validates

Get real time updates directly on you device, subscribe now.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.